Cocrystal pharma announces closing of $40 million bought deal

Bothell, wash., may 07, 2021 (globe newswire) -- cocrystal pharma, inc.  (nasdaq: cocp), (“cocrystal” or the “company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis c viruses and noroviruses, today announced the closing of its previously announced public offering of 26,000,000 shares of common stock of the company, at a price to the public of $1.54 per share, less underwriting discounts and commissions.
COCP Ratings Summary
COCP Quant Ranking